AEZS - Aeterna Zentaris Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Aeterna Zentaris Inc.

315 Sigma Drive
Summerville, SC 29486
United States
843-900-3223
http://www.zentaris.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael V. WardPres & CEO360kN/A1957
Ms. Leslie AuldSr. VP & CFO233.94kN/AN/A
Mr. Brian GarrisonSr. VP of Global Corp. Operations & Corp. Devel.270.01kN/AN/A
Dr. Nicola AmmerChief Medical Officer & VP of Clinical Devel.N/AN/AN/A
Mr. Olaf AlthausGM & MDN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Corporate Governance

Aeterna Zentaris Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.